These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11269662)

  • 1. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
    Castilleja A; Ward NE; O'Brian CA; Swearingen B; Swan E; Gillogly MA; Murray JL; Kudelka AP; Gershenson DM; Ioannides CG
    Mol Cell Biochem; 2001 Jan; 217(1-2):21-33. PubMed ID: 11269662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
    Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
    Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
    J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
    Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
    J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.
    Cohen WM; Bianco A; Connan F; Camoin L; Dalod M; Lauvau G; Ferriès E; Culmann-Penciolelli B; van Endert PM; Briand JP; Choppin J; Guillet JG
    J Virol; 2002 Oct; 76(20):10219-25. PubMed ID: 12239297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
    Knutson KL; Disis ML
    Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo.
    Gritzapis AD; Perez SA; Baxevanis CN; Papamichail M
    Br J Cancer; 2005 Jan; 92(1):72-9. PubMed ID: 15583693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat.
    Piechocki MP; Pilon SA; Kelly C; Wei WZ
    Cell Immunol; 2001 Sep; 212(2):138-49. PubMed ID: 11748930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
    Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
    Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.
    Kaplan BL; Norell H; Callender GG; Ohlum T; Kiessling R; Nishimura MI
    Cancer Immunol Immunother; 2006 Jun; 55(6):653-62. PubMed ID: 16151808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.
    Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
    Int J Cancer; 1997 Jan; 70(1):112-9. PubMed ID: 8985099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.
    Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
    J Immunol; 1999 Jul; 163(2):1037-44. PubMed ID: 10395702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.